NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded the stocks of Luminex and Qiagen to Underperform from Neutral.

Analysts Doug Schenkel and Shaun Rodriguez wrote in a research note published today that concerns about competition and a lack of "significant near-term catalysts" has led them to downgrade Luminex. "We believe competitive pressures have intensified for [Luminex's] molecular diagnostics franchise and anticipate pronounced share loss in [Respiratory Virus Panel] and a muted [Gastrointestinal Pathogen Panel] launch as a result."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.